14.46
price down icon4.55%   -0.69
after-market Handel nachbörslich: 14.46
loading
Schlusskurs vom Vortag:
$15.15
Offen:
$14.63
24-Stunden-Volumen:
3.07M
Relative Volume:
1.76
Marktkapitalisierung:
$2.62B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-323.01M
KGV:
-6.5135
EPS:
-2.22
Netto-Cashflow:
$-272.30M
1W Leistung:
-6.29%
1M Leistung:
-26.37%
6M Leistung:
-50.77%
1J Leistung:
-48.76%
1-Tages-Spanne:
Value
$14.01
$15.12
1-Wochen-Bereich:
Value
$14.01
$15.78
52-Wochen-Spanne:
Value
$12.72
$34.47

Immunovant Inc Stock (IMVT) Company Profile

Name
Firmenname
Immunovant Inc
Name
Telefon
917-580-3099
Name
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Name
Mitarbeiter
207
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMVT's Discussions on Twitter

Vergleichen Sie IMVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMVT
Immunovant Inc
14.46 2.62B 0 -323.01M -272.30M -2.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-03 Eingeleitet Jefferies Hold
2025-01-03 Herabstufung Wolfe Research Outperform → Peer Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-09 Bestätigt Oppenheimer Outperform
2024-03-28 Eingeleitet Oppenheimer Outperform
2024-03-13 Eingeleitet Goldman Buy
2024-02-20 Eingeleitet JP Morgan Overweight
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-13 Hochstufung UBS Neutral → Buy
2023-09-26 Hochstufung Raymond James Mkt Perform → Outperform
2023-05-01 Eingeleitet BofA Securities Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-31 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Stifel Buy
2023-02-15 Eingeleitet Cantor Fitzgerald Overweight
2023-02-13 Hochstufung Guggenheim Neutral → Buy
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-09-26 Herabstufung UBS Buy → Neutral
2021-12-08 Eingeleitet Wells Fargo Equal Weight
2021-08-03 Herabstufung Robert W. Baird Outperform → Neutral
2021-08-02 Herabstufung Credit Suisse Neutral → Underperform
2021-06-01 Herabstufung Guggenheim Buy → Neutral
2021-06-01 Herabstufung Stifel Buy → Hold
2020-10-28 Eingeleitet UBS Buy
2020-10-12 Eingeleitet Guggenheim Buy
2020-10-08 Eingeleitet Stifel Buy
2020-10-02 Eingeleitet Credit Suisse Outperform
2020-08-26 Bestätigt H.C. Wainwright Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-07-29 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet SVB Leerink Outperform
Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

pulisher
06:31 AM

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com

06:31 AM
pulisher
08:13 AM

Immunovant Names New CEO, CFO - marketscreener.com

08:13 AM
pulisher
08:10 AM

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - MSN

08:10 AM
pulisher
08:00 AM

Roivant Sciences Announces Leadership Changes at Immunovant - TipRanks

08:00 AM
pulisher
07:50 AM

Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - TradingView

07:50 AM
pulisher
07:50 AM

Immunovant Announces New CEO Amid Strategic Shift - TipRanks

07:50 AM
pulisher
07:18 AM

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - The Manila Times

07:18 AM
pulisher
07:00 AM

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

07:00 AM
pulisher
Apr 18, 2025

Alliancebernstein L.P. Grows Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Apr 17, 2025
pulisher
Apr 17, 2025

(IMVT) On The My Stocks Page - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Geode Capital Management LLC Boosts Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Lowers Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 15, 2025
pulisher
Apr 12, 2025

Immunovant CEO Peter Salzmann sells shares worth $364,941 By Investing.com - Investing.com South Africa

Apr 12, 2025
pulisher
Apr 12, 2025

Raymond James Financial Inc. Takes Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

Immunovant CEO Peter Salzmann sells shares worth $364,941 - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Immunovant CEO Peter Salzmann Sells Shares to Cover Tax Obligations - TradingView

Apr 11, 2025
pulisher
Apr 09, 2025

JPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Immunovant stock hits 52-week low at $13.58 amid market challenges - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Immunovant stock hits 52-week low at $13.58 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey

Apr 08, 2025
pulisher
Apr 08, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Sei Investments Co. - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

Raymond James Financial Inc. Makes New $505,000 Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

Norges Bank Purchases Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Did an AI Discriminate in Hiring? Employer Faces Lawsuit - Law.com

Apr 07, 2025
pulisher
Apr 07, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Vanguard Group Inc. - Defense World

Apr 07, 2025
pulisher
Apr 07, 2025

Immunovant, Inc. (NASDAQ:IMVT) Stock Holdings Lowered by Corebridge Financial Inc. - Defense World

Apr 07, 2025
pulisher
Apr 07, 2025

KLP Kapitalforvaltning AS Acquires Shares of 10,800 Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 07, 2025
pulisher
Apr 01, 2025

Immunovant is Now Oversold (IMVT) - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Has $377,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $41.00 - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 31, 2025

Immunovant stock hits 52-week low at $17.01 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 28, 2025

Swiss National Bank Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News

Mar 26, 2025
pulisher
Mar 24, 2025

Guggenheim Reiterates Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat

Mar 24, 2025
pulisher
Mar 22, 2025

Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News

Mar 22, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Immunovant stock hits 52-week low at $17.15 amid market challenges - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Stifel raises Immunovant stock price target to $61 from $58 By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immunovant stock holds $51 target on positive trial data By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Mar 19, 2025

Finanzdaten der Immunovant Inc-Aktie (IMVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):